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Abstract: A large number of cancer predisposing BRCA1/BRCA2 mutations have been reported, with a wide variety 
among populations. In some restricted groups, specific germline mutations in these tumor suppressor genes have been 
found with high predominance, due to a founder effect.  
We focused our review on the Italian founder mutations. 
The first Italian BRCA1 founder mutation, 5083del19, was found in Calabria: the presence of common allele in all 
carriers of this mutation (also in families with Calabrian origin living in other parts of Italy) confirmed its founder effect.
The same BRCA1 mutation was identified in the Sicilian population, but only the haplotype analysis can reveal the 
common ancestor of these groups. Another BRCA1 founder mutation, 4843delC, was found in Sicily. Four distinct 
BRCA1 mutations are attributable to families original from Tuscany: 3348delAG, 3285delA, 1499insA and 5183delTGT; 
the latter has been shown to be a founder mutation from North-Eastern Italy. The first BRCA2 mutation was identified in 
Sardinia, 8765delAG, a mutation already described as a founder mutation in Jewish-Yemenite families and also in 
French-Canadian population but with independent origins of carriers in these three populations. BRCA2 3951del3 and 
BRCA1 917delTT have been described as founder mutations in Middle Sardinia and in South and Middle Sardinia, 
respectively. 
Studies regarding prevalence and penetrance of founder mutations can allow to quantify the degree of homogeneity within 
a population and can surely help the geneticist and oncologist to simplify their choices in the genetic testing on high-risk 
families, on the basis of their ethnical origin.  
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INTRODUCTION  
 About 5-10% of breast and ovarian cancer cases are 
hereditary and a proportion of 30-50% has been attributed to 
germline mutation of BRCA1 and BRCA2 genes [1-3]. 
 Several studies have assessed the BRCA1 and BRCA2 
deleterious mutations prevalence in different cohorts, in 
particular investigating the geographical distribution as a 
consequence of a founder effect [4, 5]. Then, the BRCA1/2 
mutations distribution and prevalence in carriers with breast 
and ovarian cancer familiarity depend on population studies 
for ethnic and geographical diversity.
 The first example of a founder effect was found in 
Ashkenazi Jews population. This has ancestor from Eastern 
and Central Europe and several founder and recurrent 
mutations have been identified in this ethnically restricted 
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population. In particular three founder mutations have been 
identified, two BRCA1 and one BRCA2 mutation, present in 
up to 2.5% of Ashkenazi Jews women, compared with 0.2% 
of BRCA1/2 mutation carriers in the general population [6, 
7]. The BRCA1 185delAG mutation was found in 1% of the 
members of this population and in 20% of women with 
early-onset breast cancer (before 42y) [8]; BRCA1 5382insC 
was found in 0.13% of this ethnic group [6, 8-15] and 
BRCA2 6174delT founder mutation is present in 1.52% of 
Ashkenazi [6]. 
 The other most important founder mutations of BRCA1 
and BRCA2 genes have been described in Icelaners [6, 7, 
16], French-Canadians [17-22], Jewish-Yemenites [19, 20, 
23], Norwegians [24-27], Swedes [28-31], Finss [32, 33], 
Dutch [34-36], Spanish [37], Hispanic population [38, 39)], 
Afro-Americans [40, 41], Japanese [42-44], Chinese [45, 
46]. The most important BRCA1/2 founder mutations are 
presented in Table 1.
 This characterization of founder mutations is important 
for more accurate risk assessment and more specific genetic 
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counseling [4]. Founder mutations allowed for focused 
studies about penetrance, expression and genetic modifiers 
of risk [5]. 
 In Italy in the last ten years, a few number of founder 
recurrent mutations have been observed [47], in fact 4-27% 
of BRCA1/2 mutations recurred in unrelated families but the 
founder effect has been demonstrated only in a small number 
of mutations [48-51]. 
 The aim of this review is to examine the founder 
mutations in Italian population and to compare them with the 
same mutations detected in other populations (Tables 2, 3). 
Founder Mutations in Calabria 
 In 2001, the first case of BRCA1 founder mutation in 
Italian population was described. BRCA1 5083del19 
mutation shows have a founder effect in a geographically 
and historically homogeneus population from Calabria, 
Italian region, and it specifically characterizes such 
population and can be discovered in most of the patients 
affected by breast and ovarian cancer [52]. Twenty-four 
unrelated families at risk for breast and/or ovarian cancer 
predisposing syndrome were selected for BRCA1 genetic 
testing. six BRCA1 mutation carriers and three different 
mutations were identified. The BRCA1 5083del19 mutation 
was found in four unrelated families (33% of the overall 
mutations). All four families were from the same geographic 
area. The allelotype analysis by using five microsatellite 
markers, highlighted the common allele in all mutation 
carriers, affected and unaffected, suggesting the founder 
effect in this population, also in concordance with a 
Table 1. Most Important Founder Mutations Identified in BRCA1 and BRCA2 
Population  Mutation Reference 
Ashkenazi Jews BRCA1-185delAG,5382insC 
BRCA2-6174delT 
[6, 7-15] 




Jewish Yemenite  BRCA2-8765delAG [19, 20, 23] 
Norwegians BRCA1-1135insA,1675delA,816delGT,3348delAG [24, 27] 
Swedes BRCA1-3171ins5 [28-31] 
Finns BRCA1-IVS11+3A<G  
BRCA2-9345+1G>A,C7708T,T8555G 
[32, 33] 
Dutch BRCA1-2804delAA,IVS12-1643del3835  
BRCA2-5579insA,6503delTT 
[34, 36] 
Spanish BRCA1-5272-1G>A  
BRCA2-5374del4,5344del4,9538delAA 
[37] 
Hispanics BRCA1-S995X,2552delC,3450del4,A1708E  
BRCA2-3034del4 
[38, 39] 






Chinese BRCA1-1081delG  
BRCA2-3109c>t 
[45, 46] 
The table describes the most important founder mutations reported in the text.
Table 2. BRCA1 BRCA2 Founder Mutations in Italy 





















[50, 51, 59] 
[51, 60] 





[20, 49, 65] 
[64, 65] 
The table describes the BRCA1/BRCA2 Italian founder mutations reported in the text.
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homogeneous background of the Calabrian populations. The
research group of l’Aquila University identified the same 
mutation in two families of Calabrian origin. Allelotype 
analysis confirmed the presence of common allele [52]. 
 In 2002, a Canadian study described BRCA1 5083del19 
mutations in five out of 116 families with breast or/and 
ovarian cancer proband and at least one Italian ancestor. 
Only 3 of these have Calabrian origin [53].  
 In 2004, the “Italian Consortium of Hereditary Breast and 
Ovarian Cancer” confirmed that a few rate of 23% of 
BRCA1/2 mutation prevalence in Italian population proved 
to be recurrent in a particular geographic area. The BRCA1 
5083del19 mutation can be surely considered as the 
Calabrian founder mutation [54]. 
 A Sicily study of 2006 had shown the presence of
BRCA1 5083del19 mutation in Sicilian population. This 
mutation was found in four of 106 families selected for 
BRCA1/2 genetic test and all families confirmed their 
Sicilian origin [55]. The allelotype analysis proved the 
presence of common allele in all carriers of this mutation, 
suggesting the founder effect in Sicilian population [56]. 
Only the haplotype analysis in all BRCA1 carriers in Italy 
using the same microsatellite markers, can explain if 
Calabrian and Sicily’s families have a common ancestor 
[56]. 
Founder Mutations in Sicily 
 One hundred and six families from Sicily with familiar 
history of breast and ovarian cancer were selected to be 
submitted to BRCA1/2 mutations analysis. A new BRCA1 
4843delC mutation in the family history of breast and 
ovarian cancer in two families demonstrated high penetrance 
of this mutation.  
 Either mutation’s carriers had shown to have the same 
sequence variants. Allelotype analysis by five polymorphic 
microsatellite markers has noticed the presence of a common 
allele associated with this mutation in all the carrier subjects 
(affected and unaffected). This shows the founder effect of 
this BRCA1 4843delC mutation in the Sicilian population 
[57]. 
Founder Mutations in Tuscany 
 The Tuscany’s study has verified the founder mutations 
presence in a set of families original from the Central-
Eastern part of Tuscany. 
 One hundred and four probands with family history of 
breast and ovarian cancer were submitted to BRCA1/2 
genetic test. Thirty-five (34%) BRCA1/2 carrier families 
were detected: 22 BRCA1 with ten different mutations and 
13 BRCA2 with twelve different germline mutations [51]. 
 Four distinct BRCA1 mutations was attributable to 
families original from this geographic area [51]. 
 The BRCA1 3348delAG mutation were observed in 
twelve families, 3 male breast cancer cases original from 
Tuscany previously verified in a population study [58]; the 
BRCA1 3285delA mutation has been observed in three 
families (13/22; 57%). The haplotype analysis of nine 
microsatellite markers, proves that both have common 
haplotypes, derived from common ancestor, therefore 
demonstrating the founder effect of these mutations. The 
3348delAG mutation is estimated to have been originated 
129 generations ago, corresponding to 3,225 years [51]. 
 Also, two BRCA1 mutations 1499insA and 5183delTGT 
were detected in two unrelated families. In a previous study, 
the haplotype analysis in 1499insA mutations carriers 
revealed a founder allele originating from Western Tuscany, 
estimated to be present about 30 generations ago, or 750 
years [50, 59]. The BRCA1 5183delTGT mutation has been 
shown to be a founder mutation from North-Eastern Italy 
[51, 60]. 
 The BRCA2 mutations have the largest variability; 
9345G>A mutation has been identified in two unrelated 
families from Central-Eastern Tuscany already described in 
another patient from Tuscany [61]. The founder effect of this 
mutation hasn’t been demonstrated yet.  
Founder Mutations in Sardinia 
 Sardinia’s population shows a low level of genetic 
heterogeneity due to geographical isolation and strong 
genetic drift; then the founder effect of mutation is expected 
to be found [62, 63]. 
 In 2000, the first BRCA2 founder mutation in Italian 
breast cancer families was described. Seven breast cancer 
families with multiple affected members in the absence of 
ovarian cancer cases were selected and they all originated 
from different small villages located in the northern-central 
part of Sardinia. The BRCA2 genotyping analysis with 
markers flanking BRCA2 locus identified a common 
haplotype in four of seven families, suggesting the presence 
of a BRCA2 founder mutation. Direct sequencing allowed 
the identification of 8765delAG mutation that was found, 
besides in breast cancer probands, also in one prostate and in 
one bladder cancer patient with shared haplotype [49].
 The BRCA2 8765delAG mutation was already described 
as a founder mutation in Jewish-Yemenite families [23]  
and also in French-Canadian population [17, 18]. A previous 
study through the French-Canadian and Jewish-Yemenite 
haplotypes mutation carriers comparison, showed the 
Table 3. Common BRCA1/BRCA2 Founder Mutation 















BRCA2 8765delAG Sardinia 
Jewish-Yemenite  
French- Canadian 
[20, 49, 65] 
[19, 20, 23] 
[17-20] 
The table compare the Italian founder mutations with the same detected in other 
populations and reported in the text.
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independent origins of carriers in these two populations  
[19]. 
 In 2007, a study was conducted to evaluate the 
prevalence of BRCA2 8765delAG mutation in Sardinia 
population and to show the possible common ancestral origin 
of all mutation carriers from Sardinian and Jewish-Yemenite 
population, also referring to data among French-Canadian 
families. In North Sardinian families the identification of 
identical haplotype in all family members of BRCA2 
mutation carriers, indicated that this mutation is a founder in 
this geographic area. Moreover, the haplotype analysis 
comparison in the three analyzed populations indicated that 
BRCA2 mutation has an independent origin in these 
geographically different populations [20]. 
 Another study of 2007 described the BRCA2 3952del 
TAGinsAT mutations in six patients from a small village of 
the central part of Sardinia and with a family history of 
breast cancer. The haplotype analyses suggests that all 
mutation carriers had a common ancestor, proving the 
founder effect in Middle Sardinia population [64]. 
 A study published in 2009 [65] reports the prevalence of 
BRCA1/2 mutations in patients with positive family history 
of breast and/or ovarian cancer from Sardinia. The BRCA2 
8765delAG mutation and 3952delTAGinsAT mutation were 
previously described as founder mutations in North and 
Middle Sardinia, respectively. In three unrelated families 
from South and Middle Sardinia, was identified a BRCA1 
917delTT mutation already reported in breast/ovarian cancer 
families from Sicily [55, 56]. In this study BRCA2 mutations 
were more frequent than BRCA1 mutations, due to the high 
proportion of BRCA2 founder mutation carriers. 
Northern Italian Founder Mutations 
 The BRCA1 Val1688del (5183delTGT) deleterious 
mutation was found in a study of 1998 [66]; this mutation 
was already described in Tuscany families with North-Italian 
ancestral origins [51]. The new study in 2008, by molecular 
screening of 600 high risk breast and breast/ovarian cancer 
families, identified this variant in eight mutation carriers. 
Three additional unrelated families from Northeast Italian 
region, carriers of this variant, were added to the study [60]. 
The microsatellite markers analysis confirmed the presence 
of a common haplotype in all the 11 families, therefore 
demonstrating the common ancestor and founder effect in 
this region. Moreover, this study shows that BRCA1 
Val1688del mutation has a pathogenic effect [60]. 
Italian Founder Mutations Compared with the Same 
Mutations Detected in Other Populations 
 In a Norway study four BRCA1 mutations were reported 
that account for 68% of the BRCA1 mutation carriers: 
1675delA, 816delGT, 1135insA and 3348delAG, the latter is 
the same mutation found in Tuscany [51, 58]; the Norwegian 
families mutation carriers with breast and ovarian cancer 
history were from South-West coast of Norway [25, 26]. 
 In a 2006 study was performed haplotype analysis on 
breast and ovarian cancer families carriers of BRCA1
1135insA mutation, originating from four different geographic 
regions: French Canadian, Italian and Dutch population, 
compared with the previously reported Norway founder 
haplotype. Three distinct haplotypes were found, which 
would indicate an independent origin of this mutation in 
these populations. On the contrary, the haplotype analysis 
showed the founder effect of this mutation in Norwegian 
population [27]. 
 The founder mutations in BRCA1/BRCA2 genes were 
identified in Canadian breast and breast/ovarian cancer 
families of French ancestry. In particular, in 113 ovarian 
cancer probands unselected for family history, eight 
germline mutations were found: 5 families BRCA1 C4446T 
mutation carriers and two families BRCA2 8765delAG 
mutation carriers. The latter is the most common mutation 
described in French-Canadian breast and ovarian cancer 
families [21, 22] and was found in Italy, Sardinia population 
[17, 18]. This 8765delAG mutation was already described as 
a founder mutation in Jewish-Yemenite families [23]; the 
comparison of the three populations indicated that BRCA2 
mutation has an independent origin in these geographically 
different populations [20]. 
CONCLUSION 
 In summary, in Italy BRCA1 founder mutations are 
prevalent respect to BRCA2 founder mutations; in fact seven 
BRCA1 and two BRCA2 mutations have been detected. Two 
BRCA2 mutations were found in Sardinia region where 
BRCA2 mutations are prevalent. 
 The same BRCA1 mutations found in Calabria, which 
demonstrated to have a founder effect in this geographic 
region, were identified in the Sicilian population, but only 
the haplotype analysis can reveal the common ancestor of 
these groups. 
 Two Italian founder mutations, one BRCA1 found in 
Tuscany region and one BRCA2 detected in Sardinia region, 
were also reported in Norway and Jewish-Yemenite, French-
Canadian populations respectively; for BRCA2 mutations 
were reported the independent origins of carriers in these 
three populations. 
 The prevalence and penetrance of founder mutations in a 
population allow to focus the genetic testing on high-risk 
families, on the basis of their ethnical origin, through a more 
accurate estimate of the prior probability of carrying a 
BRCA1/2 mutation. 
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